» Articles » PMID: 35267535

Multitask Learning Radiomics on Longitudinal Imaging to Predict Survival Outcomes Following Risk-Adaptive Chemoradiation for Non-Small Cell Lung Cancer

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2022 Mar 10
PMID 35267535
Authors
Affiliations
Soon will be listed here.
Abstract

Medical imaging provides quantitative and spatial information to evaluate treatment response in the management of patients with non-small cell lung cancer (NSCLC). High throughput extraction of radiomic features on these images can potentially phenotype tumors non-invasively and support risk stratification based on survival outcome prediction. The prognostic value of radiomics from different imaging modalities and time points prior to and during chemoradiation therapy of NSCLC, relative to conventional imaging biomarker or delta radiomics models, remains uncharacterized. We investigated the utility of multitask learning of multi-time point radiomic features, as opposed to single-task learning, for improving survival outcome prediction relative to conventional clinical imaging feature model benchmarks. Survival outcomes were prospectively collected for 45 patients with unresectable NSCLC enrolled on the FLARE-RT phase II trial of risk-adaptive chemoradiation and optional consolidation PD-L1 checkpoint blockade (NCT02773238). FDG-PET, CT, and perfusion SPECT imaging pretreatment and week 3 mid-treatment was performed and 110 IBSI-compliant pyradiomics shape-/intensity-/texture-based features from the metabolic tumor volume were extracted. Outcome modeling consisted of a fused Laplacian sparse group LASSO with component-wise gradient boosting survival regression in a multitask learning framework. Testing performance under stratified 10-fold cross-validation was evaluated for multitask learning radiomics of different imaging modalities and time points. Multitask learning models were benchmarked against conventional clinical imaging and delta radiomics models and evaluated with the concordance index (c-index) and index of prediction accuracy (IPA). FDG-PET radiomics had higher prognostic value for overall survival in test folds (c-index 0.71 [0.67, 0.75]) than CT radiomics (c-index 0.64 [0.60, 0.71]) or perfusion SPECT radiomics (c-index 0.60 [0.57, 0.63]). Multitask learning of pre-/mid-treatment FDG-PET radiomics (c-index 0.71 [0.67, 0.75]) outperformed benchmark clinical imaging (c-index 0.65 [0.59, 0.71]) and FDG-PET delta radiomics (c-index 0.52 [0.48, 0.58]) models. Similarly, the IPA for multitask learning FDG-PET radiomics (30%) was higher than clinical imaging (26%) and delta radiomics (15%) models. Radiomics models performed consistently under different voxel resampling conditions. Multitask learning radiomics for outcome modeling provides a clinical decision support platform that leverages longitudinal imaging information. This framework can reveal the relative importance of different imaging modalities and time points when designing risk-adaptive cancer treatment strategies.

Citing Articles

Using high-repeatable radiomic features improves the cross-institutional generalization of prognostic model in esophageal squamous cell cancer receiving definitive chemoradiotherapy.

Gong J, Wang Q, Li J, Yang Z, Zhang J, Teng X Insights Imaging. 2024; 15(1):239.

PMID: 39373828 PMC: 11458848. DOI: 10.1186/s13244-024-01816-3.


"Under the hood": artificial intelligence in personalized radiotherapy.

Gianoli C, De Bernardi E, Parodi K BJR Open. 2024; 6(1):tzae017.

PMID: 39104573 PMC: 11299549. DOI: 10.1093/bjro/tzae017.


Delta radiomics: an updated systematic review.

Nardone V, Reginelli A, Rubini D, Gagliardi F, Del Tufo S, Belfiore M Radiol Med. 2024; 129(8):1197-1214.

PMID: 39017760 PMC: 11322237. DOI: 10.1007/s11547-024-01853-4.


Prevalence and predictive value of sarcopenia in surgically treated cholangiocarcinoma: a comprehensive review and meta-analysis.

He J, Huang Y, Huang N, Jiang J Front Oncol. 2024; 14:1363843.

PMID: 38571501 PMC: 10989063. DOI: 10.3389/fonc.2024.1363843.


Application of PET imaging delta radiomics for predicting progression-free survival in rare high-grade glioma.

Ahrari S, Zaragori T, Zinsz A, Oster J, Imbert L, Verger A Sci Rep. 2024; 14(1):3256.

PMID: 38332004 PMC: 10853227. DOI: 10.1038/s41598-024-53693-x.


References
1.
Luo Y, McShan D, Matuszak M, Ray D, Lawrence T, Jolly S . A multiobjective Bayesian networks approach for joint prediction of tumor local control and radiation pneumonitis in nonsmall-cell lung cancer (NSCLC) for response-adapted radiotherapy. Med Phys. 2018; . PMC: 6279602. DOI: 10.1002/mp.13029. View

2.
Fried D, Tucker S, Zhou S, Liao Z, Mawlawi O, Ibbott G . Prognostic value and reproducibility of pretreatment CT texture features in stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2014; 90(4):834-42. PMC: 4349397. DOI: 10.1016/j.ijrobp.2014.07.020. View

3.
Song J, Shi J, Dong D, Fang M, Zhong W, Wang K . A New Approach to Predict Progression-free Survival in Stage IV EGFR-mutant NSCLC Patients with EGFR-TKI Therapy. Clin Cancer Res. 2018; 24(15):3583-3592. DOI: 10.1158/1078-0432.CCR-17-2507. View

4.
Tomaszewski M, Gillies R . The Biological Meaning of Radiomic Features. Radiology. 2021; 298(3):505-516. PMC: 7924519. DOI: 10.1148/radiol.2021202553. View

5.
Aerts H, Bussink J, Oyen W, van Elmpt W, Folgering A, Emans D . Identification of residual metabolic-active areas within NSCLC tumours using a pre-radiotherapy FDG-PET-CT scan: a prospective validation. Lung Cancer. 2011; 75(1):73-6. DOI: 10.1016/j.lungcan.2011.06.003. View